Ken Griffin Silverback Therapeutics, Inc. Put Options Transaction History

Citadel Advisors LLC

  • $505 Billion
  • Q3 2024

Put Options

7 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q3 2024

Nov 14, 2024
BUY
N/A
111,000 Added 221.12%
161,200 $0
Q2 2024

Aug 14, 2024
BUY
N/A
8,200 Added 19.52%
50,200 $0
Q1 2024

May 15, 2024
SELL
N/A
-12,700 Reduced 23.22%
42,000 $0
Q4 2023

Feb 14, 2024
SELL
N/A
-60,900 Reduced 52.68%
54,700 $0
Q3 2023

Nov 14, 2023
BUY
N/A
92,400 Added 398.28%
115,600 $0
Q2 2023

Aug 14, 2023
BUY
N/A
21,000 Added 954.55%
23,200 $0
Q1 2023

May 15, 2023
BUY
N/A
2,200 New
2,200 $0

Others Institutions Holding SBTX

# of Institutions
163
Shares Held
62.7M
Call Options Held
872K
Put Options Held
589K
View Full List

About Silverback Therapeutics, Inc.

SBTX Quotes by TradingView
  • Ticker SBTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 35,473,800
  • Description
  • Silverback Therapeutics, Inc., a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver. Silverba...
More about SBTX
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email